Try GOLD - Free

An actor who floated freely across diverse creative credos

Business Standard

|

November 25, 2025

An elderly woman shivers in the cold. Shakti Singh alias Shaka, a criminal, spots her. The young man takes off his shirt and covers her to protect her from the elements. The act of kindness at the heart of a brief sequence in O P Ralhan’s Phool Aur Patthar, the 1966 film that catapulted Dharmendra to superstardom, became the cornerstone of the masculinity that the actor would embody — bulked-up but benign, solid but soft.

- SAIBAL CHATTERJEE

An actor who floated freely across diverse creative credos

Dharmendra’s onscreen persona contained contradictions that defied definitions. Alternating between the irrepressible and the vulnerable, the smouldering and the subdued, the handsome actor could charm a bird out of a tree.

Many a Hindi blockbuster, be it an action film, a heist thriller, a war movie, a social drama or a comedy, rode on his broad shoulders all through the 1970s and 1980s. He was never hemmed in by genres or forms.

Dharmendra floated freely across diverse creative credos. He was as much at home with Bimal Roy, Hrishikesh Mukherjee and Rajinder Singh Bedi (who directed him in 1973's Phagun) as he was with Prakash Mehra (Samadhi), Manmohan Desai (Dharam Veer) and Nasir Hussain (Yaadon Ki Baarat).

In a career that lasted more than six decades — his final film, Sriram Raghavan’s war drama Ikkis, is scheduled for release on December 25 — he went from macho to malleable, from rugged to romantic, from playful to profound and from pulpy to philosophical across a variety of movies that collectively scripted a sustained success story that was second to none.

Dharmendra’s popularity was indeed enormous. It survived the onslaughts of two megastars who arrived on the scene after the Punjab-born actor had, by the mid-1960s, established himself as one of the most bankable stars of the Hindi movie industry.

MORE STORIES FROM Business Standard

Business Standard

Labour Codes impact: HCL tech profit slips 11%

Q3 top line beats Street estimates, bottom line misses expectations

time to read

2 mins

January 13, 2026

Business Standard

New labour Codes, restructuring weigh on TCS earnings

Tata Consultancy Services (TCS), India’s largest information technology (IT) services firm, saw its profit impacted in the October-December quarter by restructuring and changes in labour Codes.

time to read

1 min

January 13, 2026

Business Standard

Business Standard

Black drives the thrill for car buyers

Sees a surge in yearly sales, while white remains practical 'utility king'

time to read

2 mins

January 13, 2026

Business Standard

CHOOSING THE RIGHT B-SCHOOL TO MATCH YOUR CAREER GOALS

Success comes when you pick an institution that fits your professional dreams and your personality, helping you become the leader you want to be

time to read

2 mins

January 13, 2026

Business Standard

Business Standard

China’s PVC rethink to help India pipe makers

Supply likely to tighten after S-PVC rebate withdrawal

time to read

2 mins

January 13, 2026

Business Standard

Responsible growth

India must ensure data centres are sustainable

time to read

2 mins

January 13, 2026

Business Standard

India’s GenZ is full of creativity: PM

Prime Minister Narendra Modi on Monday said India's GenZ is full of creativity and with innovative ideas, energy and purpose, the country’s youth is at the forefront of nation-building.

time to read

1 min

January 13, 2026

Business Standard

Business Standard

Iran wants to negotiate after threats to attack, says Trump

At least 572 killed in protests; Tehran says situation ‘under full control’

time to read

2 mins

January 13, 2026

Business Standard

Insurers knock on Irdai door for clarity on director overlap ban

CLAUSE THREATENS BOARD STRUCTURES AT BANK-BACKED FIRMS SAYS INDUSTRY

time to read

2 mins

January 13, 2026

Business Standard

Delhi HC allows Zydus to sell generic version of cancer drug

Citing public interest, the Delhi High Court has cleared the way for Zydus Life-sciences to proceed with the sale of its version of the cancer drug nivolumab in India.

time to read

1 min

January 13, 2026

Listen

Translate

Share

-
+

Change font size